Prostate Cancer & BPHArchives
Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer
Prostate Cancer & BPH 6 min.
Prostate cancer (PCa) development and progression are driven by androgens, primarily testosterone (T) and dihydrotestosterone (DHT), through activation of the androgen receptor (AR), with androgen sensitivity persisting across all disease stages [1, 2–3]. This dependency forms the basis for effective...
Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration
Prostate Cancer & BPH 5 min.
Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the USA [1, 2–3]. While early-stage PC has a favorable prognosis, survival rates decline significantly when the disease becomes metastatic or castration-resistant [3]. Androgen deprivation therapy...
Rising metastatic prostate cancer rates but narrowing racial gap
Prostate Cancer & BPH 5 min.
Black men are twice as likely to die from prostate cancer (PCa) compared to White men [1]. Although rates of more aggressive PCa subtypes appear to be higher among Black men [2, 3], a growing body of literature highlights the significant role of access to care and socioeconomic factors as major contributors...
Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives
Prostate Cancer & BPH 1 min.
To understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa)....
Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer
Prostate Cancer & BPH 4 min.
Prostate cancer is the second most common malignancy, after lung cancer, among men aged ≥ 65 years in Korea, with an age-specific incidence rate of 375.4 per 100,000 in 2020 [1]. Despite an increasing trend in incidence, prostate cancer carries one of the highest cancer survival rates, with a 5-year...
